Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

EACR 2016 /
Deciphering RAS/MAPK signalling in cancer

9th - 12th Jul 2016

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 13.07.16
Views: 2156

Dr Mariano Barbacid - CNIO, Madrid, Spain

Dr Barbacid speaks with ecancertv at EACR 2016 about results from novel mouse models to target KRAS mutations in cancer.

He describes how integrated recombinase systems, which enable the controlled expression of genes in vivo, have generated models with more readily actionable tumours for genomic and therapeutic analysis.

He also addresses recent developments in combination therapies, with regard to the risk posed by cumulative toxicity, and future of personalised therapy.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation